Immunisation of African indigenous pigs with attenuated genotype I African swine fever virus OURT88/3 induces protection against challenge with virulent strains of genotype I by Mulumba-Mfumu, LK et al.
Immunisation of African indigenous 
pigs with attenuated genotype I 
African swine fever virus OURT88/3 
induces protection against challenge 
with virulent strains of genotype I 
 
Leopold K Mulumba-Mfumu, Lynnette C. Goatley,  
Claude Saegerman, Haru-Hishe Takamatsu, Linda K. Dixon 
African swine fever virus 
(ASFV)  
• member of Asfivirus genus, Asfarviridae family 
• DNA virus (170 – 193 Kbp), with highly conserved central 
region (125 Kbp) with two terminal variable regions ( 30 
Kbp)  currently they are 22 different genotypes 
• causes an acute haemorrhagic fever in pigs and can 
induced high mortality  
• with severe socio-economic impacts 
• endemic in many sub-Saharan African countries, Sardinia 
and parts of the Trans Caucasus region and Russian 
Federation 
 
• Currently no vaccine is available to protect pigs against ASF 
and this limits options for disease control 
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Background and aim 
• Background: The attenuated African swine fever virus 
genotype I strain OURT88/3 has previously been shown 
to induce 66 to 100% of protection of European breeds 
of domestic pigs depending of the virus isolates as 
challenge (Boinas et al., 2004; King et al., 2011).  
 This strain has a large deletion near the left genome end 
compared to virulent isolates and interruptions in three other 
genes involved in immune evasion (Chapman et al., 2008). 
 
• Research question: What is the efficacy of the same 
attenuated vaccine strain in indigenous breeds of pigs 
from the DRC after challenge with autologous 
genotype 1 (2 different virulent isolates)? 
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Design and protocol of the study 
• Appropriate BSL3 facilities (equivalent) 
• Experiment approved by the ad hoc Authority 
• Virus isolates: OURT88/3 (attenuated strain) and two 
virulent strains from genotype I: OURT88/1 previously 
described (Chapman et al., 2011) and a DRC field strain 085/10. 
• Maximum five times in primary pig macrophage cultures 
• Indigenous pigs (at least 3 months old) included in the 
experiment coming from farms near Kinshasa and tested 
negative for ASFV by antibody detection ELISA and PCR   
(2 times at 30 days interval). 
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8 vaccinated (V 1) 
 IM with 104 TCID50 attenuated OURT88/3 strain 
 
 After 21 days challenged IM with 104 HAD50 OURT88/1 virulent strain 
 
 After a further 21 days, remaining pigs were challenged IM with  















7 control challenge (C 2) 
 In group B, six pigs were challenged IM with 104 HAD50 virulent 
strain OURT88/1 21 days after the start of the experiment, at 
the same time as those in group A  
 In group C, seven pigs were challenged IM with 104 HAD50 
virulent DRC strain 085/10 at 42 days at the same time that 
group A pigs were challenged with this strain 
Follow up 
• Pigs were monitored daily for clinical signs, and 
these were scored using a clinical scoring system 
previously reported (King et al., 2011).  
• Blood samples were collected at different days 
post-immunization and challenge (ELISA). At 
termination, tissue samples were collected from 
spleen, lymph nodes and kidney (PCR). 
• The ASFV genome copy numbers in blood and 
tissue samples were estimated by quantitative 
PCR (King et al., 2003). 
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Main results 
• 21 days after the second challenge (63 days after vaccine): 
– 4 pigs out 8 were immunized, 
– 4 pigs out 8 died (1 from an unknown cause) 
 
• Regarding the 4 immunized pigs with zero antibodies (Abs) 
at the beginning of the trial, showed high titers 21 days 
after the second challenge, zero clinical signs, few DNA 
copies for some and zero for others.  
 
• Regarding the 4 died pigs: 
– 1 of the 4 dead pigs was apparently killed by the sampling 
manipulation; 
– 3 killed by the challenges’ viruses (acute disease + severe signs + 
PCR positive).  
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Conclusions, perspectives and limitations 
• Despite encouraging results in terms of “efficacy” 
• The “safety” was not investigated 
• Interference between vaccine and first challenge 
on the 2d challenge outcome was not investigated 
• They are 22 genotypes of AFSV, with 3 genotypes 
in DRC (genotypes I = main, IX and XIV)  more 
experiments should be devoted to the other main 
genotypes 
• The genome of AFSV is the subject of variation  
     --> vaccination still a challenge 
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Vaccinated and 2 challenge’s surviving  pigs 
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